This Study Tests the Safety of Inhaled BAY1237592, How the Drug is

Status Completed

Clinical Trial Summary

In this trial the effects of the inhaled drug BAY1237592 will be studied in patients with high blood pressure in the pulmonary blood vessels due to Pulmonary Arterial Hypertension (PAH) and due to Chronic Thromboembolic Pulmonary Hypertension (CTEPH). Pulmonary hypertension is characterized by the elevation of pressure in the pulmonary arteries (PAP) and of the pulmonary vascular resistance (PVR) leading to increased workload of the right chamber of the heart to eject blood against this elevated resistance. The goal of this study is to measure the safety and tolerability of the drug as well as the reduction of the PVR at different doses In Part A patients without specific treatment for PH (untreated patients) will be tested. In Part B also patients stably pre-treated with specific PH drugs will be studied in combination with the new inhaled drug

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03754660
Study type	Interventional
Source	Bayer
Contact
Status	Completed
Phase	Phase 1
Start date	January 21, 2019
Completion date	November 3, 2022

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT04095286` - Relative Bioavailability Study of Marketed and Lower Dose Ambrisentan in Healthy Adult Participants	Phase 1
Enrolling by invitation	`NCT03683186` - A Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension	Phase 3
Completed	`NCT02191137` - Measuring Outcomes In Patients With Pulmonary Arterial Hypertension Not on Active Treatment (MOTION)	Phase 4
Completed	`NCT01959828` - Confirmatory Study of IK-3001 in Japanese Subjects With Peri-/Post-op Pulmonary Hypertension Assoc. With Cardiac Surgery	Phase 3
Withdrawn	`NCT01202045` - Stress Echocardiography in the Detection of Pulmonary Arterial Hypertension in Systemic Sclerosis Patients	N/A
Completed	`NCT00963001` - Effect of Food on the Pharmacokinetics of Oral Treprostinil	Phase 1
Completed	`NCT01121458` - Clevidipine for Vasoreactivity Evaluation of the Pulmonary Arterial Bed	Phase 4
Completed	`NCT00963027` - Effect of Esomeprazole on the Pharmacokinetics of Oral Treprostinil	Phase 1
Terminated	`NCT00825266` - Insulin Resistance in Pulmonary Arterial Hypertension	Phase 4
Terminated	`NCT00384865` - A Study of Aspirin and Simvastatin in Pulmonary Arterial Hypertension	Phase 2
Active, not recruiting	`NCT03926572` - Acute Decompensation of Pulmonary Hypertension	N/A
Completed	`NCT02826252` - Examination of Ventavis (Iloprost) Inhalation Behavior Using the I-Neb AAD System in Patients With Pulmonary Arterial Hypertension When Switching the Iloprost Nebulizer Solution for Inhalation From 10 μg/mL (V10) to 20 μg/mL (V20)	N/A
Completed	`NCT02545465` - A Study to Understand the Treatment Patterns in Patients With Pulmonary Arterial Hypertension or Chronic Thromboembolic Pulmonary Hypertension During a Switch of Treatment to Adempas in Real-life Clinical Practice	N/A
Recruiting	`NCT04498299` - Stress Echocardiography in Patients Recovery From Mild COVID-19 Illness
Recruiting	`NCT02558582` - Effect of Exercise Training in Patients With Pulmonary Hypertension	N/A
Active, not recruiting	`NCT02562235` - Riociguat in Children With Pulmonary Arterial Hypertension (PAH)	Phase 3
Completed	`NCT02755298` - Chronic Clinical Effect of Acetazolamide	Phase 2/Phase 3
Terminated	`NCT03043976` - Using Step Count to Enhance Daily Physical Activity in Pulmonary Hypertension	N/A
Completed	`NCT02576002` - Epidemiology and Treatment Patterns of Paediatric PAH (Pulmonary Arterial Hypertension)	N/A
Completed	`NCT01178073` - A Study of First-Line Ambrisentan and Tadalafil Combination Therapy in Subjects With Pulmonary Arterial Hypertension (PAH)	Phase 3